Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJMBR (2) Autor Barreiro,E.J. (1) Barreto,A.C. (1) Campos,H.S. (1) Carnielli,D. (1) Castro,C.R.P. (1) Faffe,D.S. (1) Franchi,S.M. (1) Lapa e Silva,J.R. (1) Lima,L.M. (1) Lopes,A.A. (1) Mauad,T. (1) Negri,E.M. (1) Oliveira,M.B.G. (1) Rocco,P.R.M. (1) Teixeira,I. (1) Xisto,D.G. (1) Zin,W.A. (1) Mais... Palavra-chave Phosphodiesterase inhibitors (2) Asthma (1) BALB/c mice (1) Lung function (1) Pulmonary hypertension (1) Pulmonary veno-occlusive disease (1) Sildenafil (1) Steroid (1) Mais... Tipo do documento Info:eu-repo/semantics/article (1) Info:eu-repo/semantics/other (1) Ano 2006 (1) 2005 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease BJMBR Barreto,A.C.; Franchi,S.M.; Castro,C.R.P.; Lopes,A.A.. We hypothesized that chronic oral administration of the phosphodiesterase-5 inhibitor sildenafil could improve the exercise capacity and pulmonary hemodynamics in patients with pulmonary arterial hypertension (PAH) on the basis of previous short-term studies. We tested this hypothesis in 14 subjects with PAH, including seven patients with the idiopathic form and seven patients with atrial septal defects, but no other congenital heart abnormalities. Patients were subjected to a 6-min walk test and dyspnea was graded according to the Borg scale. Pulmonary flow and pressures were measured by Doppler echocardiography. Patients were given sildenafil, 75 mg orally three times a day, and followed up for 1 year. Sildenafil therapy resulted in the following... Tipo: Info:eu-repo/semantics/article Palavras-chave: Sildenafil; Pulmonary hypertension; Pulmonary veno-occlusive disease; Phosphodiesterase inhibitors. Ano: 2005 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005000200006 Protective effects of phosphodiesterase inhibitors on lung function and remodeling in a murine model of chronic asthma BJMBR Campos,H.S.; Xisto,D.G.; Oliveira,M.B.G.; Teixeira,I.; Negri,E.M.; Mauad,T.; Carnielli,D.; Lima,L.M.; Barreiro,E.J.; Faffe,D.S.; Zin,W.A.; Lapa e Silva,J.R.; Rocco,P.R.M.. The aim of the present study was to compare the efficacy of a novel phosphodiesterase 4 and 5 inhibitor, LASSBio596, with that of dexamethasone in a murine model of chronic asthma. Lung mechanics (airway resistance, viscoelastic pressure, and static elastance), histology, and airway and lung parenchyma remodeling (quantitative analysis of collagen and elastic fiber) were analyzed. Thirty-three BALB/c mice were randomly assigned to four groups. In the asthma group (N = 9), mice were immunized with 10 µg ovalbumin (OVA, ip) on 7 alternate days, and after day 40 they were challenged with three intratracheal instillations of 20 µg OVA at 3-day intervals. Control mice (N = 8) received saline under the same protocol. In the dexamethasone (N = 8) and LASSBio596... Tipo: Info:eu-repo/semantics/other Palavras-chave: Asthma; Lung function; Steroid; Phosphodiesterase inhibitors; BALB/c mice. Ano: 2006 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000200016 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco